On Invalid Date, Sangamo Therapeutics (NASDAQ: SGMO) reported Q3 2022 earnings per share (EPS) of -$0.34, up 3.03% year over year. Total Sangamo Therapeutics earnings for the quarter were -$53.16 million. In the same quarter last year, Sangamo Therapeutics's earnings per share (EPS) was -$0.33.
As of Q1 2023, Sangamo Therapeutics's earnings has grown year over year. Sangamo Therapeutics's earnings in the past year totalled -$177.80 million.
What is SGMO's earnings date?
Sangamo Therapeutics's earnings date is Invalid Date. Add SGMO to your watchlist to be reminded of SGMO's next earnings announcement.
What was SGMO's revenue last quarter?
On Invalid Date, Sangamo Therapeutics (NASDAQ: SGMO) reported Q3 2022 revenue of $26.46 million up 7.36% year over year. In the same quarter last year, Sangamo Therapeutics's revenue was $28.56 million.
What was SGMO's revenue growth in the past year?
As of Q1 2023, Sangamo Therapeutics's revenue has grown 3.26% year over year. This is 120.25 percentage points lower than the US Biotechnology industry revenue growth rate of 123.51%. Sangamo Therapeutics's revenue in the past year totalled $112.06 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.